Royal Bank of Canada’s NewAmsterdam Pharma NAMS Stock Holding History

Royal Bank of Canada’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$487K	Buy	14,362 +3,048	+27%	+$100K	﹤0.01%	4387
2026 Q1	$362K	Sell	11,314 -12,770	-53%	-$416K	﹤0.01%	4358
2025 Q4	$846K	Sell	24,084 -2,418	-9%	-$88K	﹤0.01%	3778
2025 Q3	$754K	Buy	26,502 +8,170	+45%	+$196K	﹤0.01%	4197
2025 Q2	$332K	Buy	18,332 +8,996	+96%	+$164K	﹤0.01%	4775
2025 Q1	$191K	Sell	9,336 -11,022	-54%	-$245K	﹤0.01%	4736
2024 Q4	$524K	Buy	20,358 +11,401	+127%	+$242K	﹤0.01%	4055
2024 Q3	$149K	Buy	8,957 +151	+2%	+$2.61K	﹤0.01%	5050
2024 Q2	$169K	Buy	8,806 +5,356	+155%	+$107K	﹤0.01%	4897
2024 Q1	$82K	Sell	3,450 -7,425	-68%	-$151K	﹤0.01%	5295
2023 Q4	$121K	Buy	10,875 +9,875	+988%	+$90.4K	﹤0.01%	5496
2023 Q3	$9K	Buy	+1,000	New	+$10.8K	﹤0.01%	6460

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Royal Bank of Canada's NAMS Position: Q2 2026 in Review

Royal Bank of Canada increased its NewAmsterdam Pharma (NAMS) stake by 27% in Q2 2026, buying an estimated $100K and bringing the position to 14,362 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

Royal Bank of Canada first reported a position in NAMS in Q3 2023 and has held it in 12 quarters since. The position peaked at $846K in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Royal Bank of Canada held 14,362 shares of NewAmsterdam Pharma worth $487K as of Q2 2026.
Royal Bank of Canada bought 3,048 NewAmsterdam Pharma shares in Q2 2026, an estimated $100K.
NewAmsterdam Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4387 holding.
Royal Bank of Canada first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 12 quarters since.
Royal Bank of Canada's NewAmsterdam Pharma position peaked at $846K in Q4 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.